Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
51
RPRX Quote, Financials, Valuation and Earnings
Last price:
$39.14
Seasonality move
:
6.41%
Day range:
$38.98 - $39.64
52-week range:
$24.05 - $41.24
Dividend yield:
2.22%
P/E ratio:
22.65x
P/S ratio:
9.64x
P/B ratio:
2.64x
Volume:
3.1M
Avg. volume:
4.1M
1-year change:
50%
Market cap:
$16.9B
Revenue:
$2.3B
EPS (TTM):
$1.75
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RPRX
Royalty Pharma Plc
|
$763.5M | $1.04 | 37.45% | 181.03% | $45.54 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$974.1M | $1.75 | 97.59% | -58.59% | $492.17 |
|
AMGN
Amgen, Inc.
|
$9B | $5.01 | 4.56% | 309.55% | $324.25 |
|
LLY
Eli Lilly & Co.
|
$16.1B | $5.89 | 30.84% | 53.75% | $1,045.59 |
|
PFE
Pfizer Inc.
|
$16.5B | $0.63 | -1.98% | 745.84% | $29.04 |
|
ZBIO
Zenas BioPharma, Inc.
|
$10M | -$0.85 | 1166.67% | -5.46% | $45.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RPRX
Royalty Pharma Plc
|
$39.60 | $45.54 | $16.9B | 22.65x | $0.22 | 2.22% | 9.64x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$465.34 | $492.17 | $61.5B | 1,934.89x | $0.00 | 0% | 19.09x |
|
AMGN
Amgen, Inc.
|
$340.16 | $324.25 | $183.2B | 26.30x | $2.38 | 2.8% | 5.13x |
|
LLY
Eli Lilly & Co.
|
$1,033.56 | $1,045.59 | $925.1B | 51.12x | $1.50 | 0.58% | 15.86x |
|
PFE
Pfizer Inc.
|
$25.57 | $29.04 | $145.4B | 14.90x | $0.43 | 6.73% | 2.32x |
|
ZBIO
Zenas BioPharma, Inc.
|
$36.67 | $45.00 | $1.5B | -- | $0.00 | 0% | 102.44x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RPRX
Royalty Pharma Plc
|
58.29% | 0.918 | 49.28% | 3.47x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.279 | 4.61% | 2.37x |
|
AMGN
Amgen, Inc.
|
85.02% | 0.027 | 35.92% | 0.82x |
|
LLY
Eli Lilly & Co.
|
64.11% | -0.293 | 6.22% | 0.65x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
|
ZBIO
Zenas BioPharma, Inc.
|
0.41% | 0.444 | 0.09% | 5.55x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RPRX
Royalty Pharma Plc
|
$608M | $427.2M | 7.29% | 13.15% | 70.11% | -$258.4M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
AMGN
Amgen, Inc.
|
$6.5B | $2.6B | 10.74% | 95.55% | 26.65% | $4.2B |
|
LLY
Eli Lilly & Co.
|
$14.6B | $8.4B | 33.81% | 106.26% | 47.65% | $6B |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
|
ZBIO
Zenas BioPharma, Inc.
|
-$11K | -$47.6M | -67.98% | -68.2% | -373.3% | -$41.1M |
Royalty Pharma Plc vs. Competitors
-
Which has Higher Returns RPRX or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of 72.91% compared to Royalty Pharma Plc's net margin of 20.1%. Royalty Pharma Plc's return on equity of 13.15% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.
Company Gross Margin Earnings Per Share Invested Capital RPRXRoyalty Pharma Plc99.79% $0.67 $18.6B ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B -
What do Analysts Say About RPRX or ALNY?
Royalty Pharma Plc has a consensus price target of $45.54, signalling upside risk potential of 16.12%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $492.17 which suggests that it could grow by 5.77%. Given that Royalty Pharma Plc has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Royalty Pharma Plc is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RPRXRoyalty Pharma Plc5 1 0 ALNYAlnylam Pharmaceuticals, Inc.14 7 0 -
Is RPRX or ALNY More Risky?
Royalty Pharma Plc has a beta of 0.466, which suggesting that the stock is 53.41% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.301, suggesting its less volatile than the S&P 500 by 69.879%.
-
Which is a Better Dividend Stock RPRX or ALNY?
Royalty Pharma Plc has a quarterly dividend of $0.22 per share corresponding to a yield of 2.22%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma Plc pays 43.94% of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Royalty Pharma Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RPRX or ALNY?
Royalty Pharma Plc quarterly revenues are $609.3M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Royalty Pharma Plc's net income of $444.2M is higher than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Royalty Pharma Plc's price-to-earnings ratio is 22.65x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,934.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma Plc is 9.64x versus 19.09x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RPRXRoyalty Pharma Plc9.64x 22.65x $609.3M $444.2M ALNYAlnylam Pharmaceuticals, Inc.19.09x 1,934.89x $1.2B $251.1M
-
Which has Higher Returns RPRX or AMGN?
Amgen, Inc. has a net margin of 72.91% compared to Royalty Pharma Plc's net margin of 33.55%. Royalty Pharma Plc's return on equity of 13.15% beat Amgen, Inc.'s return on equity of 95.55%.
Company Gross Margin Earnings Per Share Invested Capital RPRXRoyalty Pharma Plc99.79% $0.67 $18.6B AMGNAmgen, Inc.67.85% $5.93 $64.2B -
What do Analysts Say About RPRX or AMGN?
Royalty Pharma Plc has a consensus price target of $45.54, signalling upside risk potential of 16.12%. On the other hand Amgen, Inc. has an analysts' consensus of $324.25 which suggests that it could fall by -4.68%. Given that Royalty Pharma Plc has higher upside potential than Amgen, Inc., analysts believe Royalty Pharma Plc is more attractive than Amgen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RPRXRoyalty Pharma Plc5 1 0 AMGNAmgen, Inc.10 15 2 -
Is RPRX or AMGN More Risky?
Royalty Pharma Plc has a beta of 0.466, which suggesting that the stock is 53.41% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.
-
Which is a Better Dividend Stock RPRX or AMGN?
Royalty Pharma Plc has a quarterly dividend of $0.22 per share corresponding to a yield of 2.22%. Amgen, Inc. offers a yield of 2.8% to investors and pays a quarterly dividend of $2.38 per share. Royalty Pharma Plc pays 43.94% of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend. Royalty Pharma Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen, Inc.'s is not.
-
Which has Better Financial Ratios RPRX or AMGN?
Royalty Pharma Plc quarterly revenues are $609.3M, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. Royalty Pharma Plc's net income of $444.2M is lower than Amgen, Inc.'s net income of $3.2B. Notably, Royalty Pharma Plc's price-to-earnings ratio is 22.65x while Amgen, Inc.'s PE ratio is 26.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma Plc is 9.64x versus 5.13x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RPRXRoyalty Pharma Plc9.64x 22.65x $609.3M $444.2M AMGNAmgen, Inc.5.13x 26.30x $9.6B $3.2B
-
Which has Higher Returns RPRX or LLY?
Eli Lilly & Co. has a net margin of 72.91% compared to Royalty Pharma Plc's net margin of 31.72%. Royalty Pharma Plc's return on equity of 13.15% beat Eli Lilly & Co.'s return on equity of 106.26%.
Company Gross Margin Earnings Per Share Invested Capital RPRXRoyalty Pharma Plc99.79% $0.67 $18.6B LLYEli Lilly & Co.82.91% $6.21 $66.4B -
What do Analysts Say About RPRX or LLY?
Royalty Pharma Plc has a consensus price target of $45.54, signalling upside risk potential of 16.12%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,045.59 which suggests that it could grow by 1.16%. Given that Royalty Pharma Plc has higher upside potential than Eli Lilly & Co., analysts believe Royalty Pharma Plc is more attractive than Eli Lilly & Co..
Company Buy Ratings Hold Ratings Sell Ratings RPRXRoyalty Pharma Plc5 1 0 LLYEli Lilly & Co.17 8 0 -
Is RPRX or LLY More Risky?
Royalty Pharma Plc has a beta of 0.466, which suggesting that the stock is 53.41% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.
-
Which is a Better Dividend Stock RPRX or LLY?
Royalty Pharma Plc has a quarterly dividend of $0.22 per share corresponding to a yield of 2.22%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. Royalty Pharma Plc pays 43.94% of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RPRX or LLY?
Royalty Pharma Plc quarterly revenues are $609.3M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Royalty Pharma Plc's net income of $444.2M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Royalty Pharma Plc's price-to-earnings ratio is 22.65x while Eli Lilly & Co.'s PE ratio is 51.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma Plc is 9.64x versus 15.86x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RPRXRoyalty Pharma Plc9.64x 22.65x $609.3M $444.2M LLYEli Lilly & Co.15.86x 51.12x $17.6B $5.6B
-
Which has Higher Returns RPRX or PFE?
Pfizer Inc. has a net margin of 72.91% compared to Royalty Pharma Plc's net margin of 21.32%. Royalty Pharma Plc's return on equity of 13.15% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital RPRXRoyalty Pharma Plc99.79% $0.67 $18.6B PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About RPRX or PFE?
Royalty Pharma Plc has a consensus price target of $45.54, signalling upside risk potential of 16.12%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13.57%. Given that Royalty Pharma Plc has higher upside potential than Pfizer Inc., analysts believe Royalty Pharma Plc is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings RPRXRoyalty Pharma Plc5 1 0 PFEPfizer Inc.7 15 1 -
Is RPRX or PFE More Risky?
Royalty Pharma Plc has a beta of 0.466, which suggesting that the stock is 53.41% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock RPRX or PFE?
Royalty Pharma Plc has a quarterly dividend of $0.22 per share corresponding to a yield of 2.22%. Pfizer Inc. offers a yield of 6.73% to investors and pays a quarterly dividend of $0.43 per share. Royalty Pharma Plc pays 43.94% of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend. Royalty Pharma Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer Inc.'s is not.
-
Which has Better Financial Ratios RPRX or PFE?
Royalty Pharma Plc quarterly revenues are $609.3M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Royalty Pharma Plc's net income of $444.2M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Royalty Pharma Plc's price-to-earnings ratio is 22.65x while Pfizer Inc.'s PE ratio is 14.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma Plc is 9.64x versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RPRXRoyalty Pharma Plc9.64x 22.65x $609.3M $444.2M PFEPfizer Inc.2.32x 14.90x $16.7B $3.6B
-
Which has Higher Returns RPRX or ZBIO?
Zenas BioPharma, Inc. has a net margin of 72.91% compared to Royalty Pharma Plc's net margin of -335.73%. Royalty Pharma Plc's return on equity of 13.15% beat Zenas BioPharma, Inc.'s return on equity of -68.2%.
Company Gross Margin Earnings Per Share Invested Capital RPRXRoyalty Pharma Plc99.79% $0.67 $18.6B ZBIOZenas BioPharma, Inc.-- -$1.22 $197.2M -
What do Analysts Say About RPRX or ZBIO?
Royalty Pharma Plc has a consensus price target of $45.54, signalling upside risk potential of 16.12%. On the other hand Zenas BioPharma, Inc. has an analysts' consensus of $45.00 which suggests that it could grow by 22.72%. Given that Zenas BioPharma, Inc. has higher upside potential than Royalty Pharma Plc, analysts believe Zenas BioPharma, Inc. is more attractive than Royalty Pharma Plc.
Company Buy Ratings Hold Ratings Sell Ratings RPRXRoyalty Pharma Plc5 1 0 ZBIOZenas BioPharma, Inc.7 0 0 -
Is RPRX or ZBIO More Risky?
Royalty Pharma Plc has a beta of 0.466, which suggesting that the stock is 53.41% less volatile than S&P 500. In comparison Zenas BioPharma, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RPRX or ZBIO?
Royalty Pharma Plc has a quarterly dividend of $0.22 per share corresponding to a yield of 2.22%. Zenas BioPharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma Plc pays 43.94% of its earnings as a dividend. Zenas BioPharma, Inc. pays out -- of its earnings as a dividend. Royalty Pharma Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RPRX or ZBIO?
Royalty Pharma Plc quarterly revenues are $609.3M, which are larger than Zenas BioPharma, Inc. quarterly revenues of --. Royalty Pharma Plc's net income of $444.2M is higher than Zenas BioPharma, Inc.'s net income of -$51.5M. Notably, Royalty Pharma Plc's price-to-earnings ratio is 22.65x while Zenas BioPharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma Plc is 9.64x versus 102.44x for Zenas BioPharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RPRXRoyalty Pharma Plc9.64x 22.65x $609.3M $444.2M ZBIOZenas BioPharma, Inc.102.44x -- -- -$51.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
39
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
